Browsing category:

Anti-Hypertensive


Entresto, the novel combination therapy which combines Sacubitril and Valsartan, was FDA approved on July 7, 2015. Previously known as the investigational compound LCZ696, Entresto received an FDA nod to reduce the risk of both hospitalization and cardiovascular mortality in patients with chronic heart failure, especially those with a reduced ejection fraction and an NYHA[…]

Read More

A new study published in the January 2015 Investigative Ophthalmology & Visual Science has shared alarming news regarding patients who suffer from long-term or chronic hypertension. Information gleaned from studies has revealed that people who are diagnosed with hypertension and who do not treat their condition are at a heightened risk for glaucoma. Ophthalmologists and[…]

Read More

By 2020 Glaucoma is predicted to affect over 80 million people worldwide as one of the leading causes of vision loss in adults. Approximately 10 percent of the patients diagnosed with Glaucoma will become bilaterally blind from this disease. Treatment to effectively and safely lower intraocular pressure is a must, with a growing rate of[…]

Read More

The FDA concluded its safety review of the popular anti-hypertensive drug Olmesartan, also known as the brand name Benicar, in June 2014. There was no viable evidence found to cause the FDA to deem Olmesartan unsafe, and earlier concerns from study investigators claiming there was an increased risk for heart attack in patients taking Olmesartan[…]

Read More

Recent data gleaned from a successful Phase III study of Selexipag sent stock prices up fifteen percent for the pharmaceutical company Actelion. As an efficacious next generation treatment for pulmonary arterial hypertension, also known as PAH, Selexipag has been forecasted by pharmaceutical analysts to become the next blockbuster drug. The advent of Selexipag as an[…]

Read More